Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

The Jiangsu Government's Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com ), is working with Jiangsu University and Nanjing University's Drum Tower Hospital to fulfill the grant's requirements.

9 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple sclerosis.

7 Jan 2010

Positive top-line results from Phase III study of aclidinium bromide announced

orest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced positive top-line results from ACCORD COPD I, a three-month Phase III study comparing aclidinium 200µg and 400µg BID versus placebo.

7 Jan 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

6 Jan 2010

NFCA and Partners Against Pain team up to create new Caregiver Cornerstones resource

The National Family Caregivers Association (NFCA) has teamed up with the national pain management education program, Partners Against Pain®, and advocate and author Lee Woodruff to create the new Caregiver Cornerstones resource.

6 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

HIRU and HTDS announce finalization of MindUp BioResearch Division sale

This is a joint press release of Hiru Corporation (HIRU) and Hard to Treat Diseases (HTDS) - The two companies are pleased to announce the finalization and completion of the purchase and sale of the MindUp BioResearch Division. Details of the transaction completed on cash and stock basis can be found at the Pink Sheets web site www.pinksheets.com under the "filings" tab.

3 Jan 2010

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

TENS therapy is not effective against chronic low-back pain

A new guideline issued by the American Academy of Neurology finds that transcutaneous electric nerve stimulation (TENS), a widely used pain therapy involving a portable device, is not recommended to treat chronic low-back pain that has persisted for three months or longer because research shows it is not effective.

31 Dec 2009

Healthcare management application targeting MS patients released

A Pennsylvania-based company has just released a healthcare management application that targets Multiple Sclerosis (MS) patients to the App Store.

29 Dec 2009

Nutrient-rich foods for weight loss

For the majority of Americans who are unhappy with their weight at any given moment, the New Year brings mixed emotions: the renewed resolution to shed pounds and the challenge of learning how to eat right to reach those goals.

29 Dec 2009

Senate health care bill will increase patient access and help create high-wage, high-value jobs

“These provisions mean increased access for the patients of today and renewed hope for the patients of tomorrow. In addition, they will help create high-wage, high-value jobs in our nation’s burgeoning biotech sector and help maintain U.S. global leadership in innovation.”

28 Dec 2009

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine.

23 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

Opexa Therapeutics completes registered direct offering

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series

18 Dec 2009

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

Positive top-line results from Phase III study of aclidinium bromide announced

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

NFCA and Partners Against Pain team up to create new Caregiver Cornerstones resource

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

HIRU and HTDS announce finalization of MindUp BioResearch Division sale

Sharing Miracles: A TV program that features inspirational stories of real patients

TENS therapy is not effective against chronic low-back pain

Healthcare management application targeting MS patients released

Nutrient-rich foods for weight loss

Senate health care bill will increase patient access and help create high-wage, high-value jobs

Study reveals genomic switches separate autoimmune disorders in different clusters

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

UAB professors honored for scientific contributions and outstanding mentorship

Opexa Therapeutics completes registered direct offering

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in